miR-126 Drives Quiescence and Self-Renewal in Leukemic Stem Cells

Leukemic stem cells (LSCs) are resistant to conventional chemotherapy and promote acute myeloid leukemia (AML) progression and recurrence. In this issue of Cancer Cell, Lechman and colleagues (2016) identify the microRNA miR-126 as a regulator of PI3K-AKT-mTOR and CDK3 signaling driving LSC self-ren...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer cell 2016-02, Vol.29 (2), p.133-135
Hauptverfasser:	Raffel, Simon, Trumpp, Andreas
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Hematopoietic Stem Cells - pathology Humans Leukemia, Myeloid, Acute - pathology MicroRNAs - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Leukemic stem cells (LSCs) are resistant to conventional chemotherapy and promote acute myeloid leukemia (AML) progression and recurrence. In this issue of Cancer Cell, Lechman and colleagues (2016) identify the microRNA miR-126 as a regulator of PI3K-AKT-mTOR and CDK3 signaling driving LSC self-renewal and chemotherapy resistance. Leukemic stem cells (LSCs) are resistant to conventional chemotherapy and promote acute myeloid leukemia (AML) progression and recurrence. In this issue of Cancer Cell, Lechman and colleagues (2016) identify the microRNA miR-126 as a regulator of PI3K-AKT-mTOR and CDK3 signaling driving LSC self-renewal and chemotherapy resistance.
ISSN:	1535-6108 1878-3686
DOI:	10.1016/j.ccell.2016.01.007